Rubicon Research Ltd.
Fundamentals
- Market cap
- ₹23,428 cr
- P/E
- 94.95×
- ROE
- 24.84%
- Debt / equity
- 0.73
- Div yield
- 0.11%
- 52-week range
- 570.75 — 1468.70
Company snapshot
Rubicon Research Ltd.
Pharmaceuticals
₹21,545 cr
P/E 87.32×
Latest quarter · Mar 2026
Sales₹514 cr
Net profit₹77 cr
Op. margin+23.1%
EPS₹4.65
Strength & growth
Debt / equity0.73×
Current ratio1.35×
The timeline — 3 notes on Rubicon Research Ltd.
May 2026
- 29 May 26 · 9:03 PM IST Brief Brief · Concalls · Large cap
Rubicon's profit doubled. Its factory is still a year away.
Q4 revenue jumped 44% to ₹514 cr, but reliance on outsourced manufacturing is squeezing gross margins. Pithampur commissioning is the fix.
- 29 May 26 · 7:22 PM IST Brief Brief · Earnings · Large cap
Rubicon's profit grows twice as fast as its revenue
Net profit surged 83.6% on 36.6% revenue growth. A clean audit and a ₹1.50 dividend seal the year.